Showing 431-440 of 6977 results for "".
Evidence-based Skincare
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/evidence-based-skincare/18491/Evidence-based skincare is the foundation of a 360-degree cosmetic rejuvenation plan, says Shannon Humphrey, MD. Hear her number 1 recommendation for all aesthetic patients.Neotensil®: A Novel, Noninvasive Solution That Reduces the Appearance of Under-Eye Bags
https://practicaldermatology.com/topics/practice-management/neotensil-a-novel-noninvasive-solution-that-reduces-the-appearance-of-under-eye-bags/19058/Neotensil is the only noninvasive solution clinically proven to reduce the appearance of under-eye bags within an hour, with benefits that last up to 16 hours. Doris Day, MD, discusses the benefits of Neotensil, as well as patient selection, staff training and how to incorporate this unique and effeJoel Schlessinger MD Explains How a Spa Helped Build His Practice
https://practicaldermatology.com/topics/practice-management/joel-schlessinger-md-explains-how-a-spa-helped-build-his-practice-/19156/As the dermatology and skin care industry expands, the opportunity to offer new procedures, techniques and products for your patients grows. One way that Joel Schlessinger MD chose to advance his business was by adding a spa on to his current practice. In this video, he explains how the decision helDistinguishing Transient Pediatric Atopic Dermatitis from Persistent or Early-onset Atopic March Cases
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37150/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, discusses clinical predictors of transient atopic dermatitis vs early-onset atopic march.Addressing Equity Gaps in Psoriasis Research
https://practicaldermatology.com/series/c-suite-chats/addressing-equity-gaps-in-psoriasis-research/33151/LaShell Robinson, Head, Global Feasibility and Trial Equity for Takeda, discusses the disproportionate underrepresentation of certain racial and ethnic groups in clinical trials, especially for psoriasis, and how Takeda is seeking to close those gaps in recent Phase 3 trials.Nemluvio Gains Two Major Indications in Europe
https://practicaldermatology.com/series/dermwire-tv/nemluvio-gains-two-major-indications-in-europe/32982/In this week's DermwireTV, Nemluvio is approved for two new indications in Europe; new patient-centric guidelines for generalized pustular psoriasis (GPP) management are unveiled; and in our C-Suite Chats feature, we are joined by the Co-Founder and CEO of Veradermics.Pediatric, Acne, and AD Sessions: Dr. Eichenfield
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/pediatric-acne-and-ad-sessions-dr-eichenfield/32684/Lawrence Eichenfield, MD, discusses his presentations from Maui Derm 2025, which included "Pediatric Dermatology 2025," "Update 2025: Acne and Rosacea," and "Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2025." Highlights include the importance of recognizing severe and rapidEpidermal Inclusion Cysts: Dr. Goldman
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/epidermal-inclusion-cysts-dr-goldman/32687/Mitchel Goldman, MD, who took part in the "Neuromodulator and Dermal Filler" panel at Maui Derm 2025, talks about a new treatment for epidermal inclusion cysts, involving sclerotherapy medication.Clinical Development of Emrosi for Rosacea
https://practicaldermatology.com/series/c-suite-chats/clinical-development-emrosi-rosacea/32379/Claude Maraoui, President and CEO of Journey Medical, discusses the clinical development program for Emrosi, which was recently approved by the FDA for inflammatory lesions of rosacea in adults.ASDS: Ethics and Social Media Panel Discussion
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-ethics-and-social-media-panel-discussion/29153/Drs. Fatima Fahs, Kavita Mariwalla, DiAnne Davis, and Evan Rieder recap key points from their panel discussion on ethics and social media at the 2024 American Society for Dermatologic Surgery Annual Meeting.